Amgen vs Tesla: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and Tesla side by side

1. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

2. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

3. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

4. 1985Amgen

   G-CSF cloned, leading to Neupogen

   While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

5. 1989Amgen

   FDA approves Epogen

   The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

6. 1991Amgen

   Neupogen approved, giving Amgen a second franchise

   The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

7. 1991Amgen

   Amgen wins the erythropoietin patent fight

   On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

8. 2001Amgen

   FDA approves Aranesp, the longer-acting EPO

   Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

9. 2002Amgen

   US$16 billion Immunex acquisition brings Enbrel in-house

   Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

10. 2003Tesla

    Tesla Motors Founded

    Tesla Motors was founded in 2003 by Martin Eberhard and Marc Tarpenning to prove that lithium-ion batteries could power a desirable electric car.

11. 2004Tesla

    Elon Musk Leads Series A

    Elon Musk led Tesla's Series A financing in 2004 and became chairman. The investment gave Tesla enough capital and public credibility to continue Roadster development.

12. 2008Tesla

    Roadster Launch

    The Roadster launched in 2008 as a highway-capable electric sports car with more than 200 miles of range. It mattered because it proved an EV could be fast, premium and emotionally desirable.

13. 2008Tesla

    Elon Musk Becomes CEO

    Musk became CEO in 2008 during a severe financing and production crisis. He restructured operations, secured emergency funding and pushed the company toward a clearer product sequence.

14. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

15. 2010Tesla

    Tesla IPO

    Tesla went public in 2010, raising capital while still far from stable profitability. The IPO mattered because it gave Tesla access to public-market funding for product development and manufacturing.

16. 2012Tesla

    Model S Launch

    The Model S launched in 2012 and moved Tesla beyond the Roadster niche. It mattered because it combined range, software, performance and premium design in a vehicle Tesla controlled more fully.

17. 2014Tesla

    Gigafactory Strategy Announced

    Tesla announced the Gigafactory strategy in 2014 with Panasonic as a key partner. The move mattered because batteries were the limiting input for EV scale, cost and range.

18. 2016Tesla

    SolarCity Acquired

    Tesla's 2016 SolarCity acquisition is company-specific because it changed the portfolio rather than simply adding scale. The reported value was $2.6B.

19. 2017Tesla

    Model 3 Production Crisis

    The Model 3 ramp in 2017 exposed severe bottlenecks caused partly by excessive automation. The crisis mattered because Tesla's mass-market strategy depended on producing a lower-priced vehicle at high volume.

20. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

21. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

22. 2020Tesla

    S&P 500 Inclusion

    Tesla joined the S&P 500 in 2020 after proving sustained profitability. The milestone mattered because it brought index-fund ownership, wider institutional attention and validation that Tesla was no longer a speculative startup.

23. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

24. 2023Tesla

    Global Price Cuts

    Tesla cut prices across major markets in 2023 to defend demand and pressure competitors. The move mattered because it showed Tesla could use its direct-sales model to adjust faster than dealer-based rivals.

25. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

26. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

27. 2025Tesla

    $94.8B Revenue and Delivery Decline

    In FY2025, Tesla reported $94.8B in revenue and delivered 1,636,129 vehicles. The milestone mattered because revenue and deliveries both showed the company had entered a more mature, contested phase.

28. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

Acquisitions

Questions about Amgen vs Tesla